Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View

Dr. Sara Dong

Transplant/Immunocompromised States · Boston Children's Hospital

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Keith Kaye

General ID · RU

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Kelly Dooley

Mycobacterial Disease · Vanderbilt

View

Dr. Erin Bonura

General ID · OHSU

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Comparative Outcomes of Babesiosis in Immunocompromised and Nonimmunocompromised Hosts: A Multicenter Cohort Study.

    Dec 24, 2025DOI: 10.1093/cid/ciaf034Journal ArticleCID

    Written by: Loukas KakoullisCarolyn D AlonsoRebecca BurnsMuneerah M AleissaEsther Arbona HaddadAndy J KimRebecca RooksBridget YatesUrwah KanwalNicholas P MorrealeAlexandra MorganRamy ArnaoutAlexandra TongNatalie E IzaguirreJessica S LittleSarah P HammondMary W MontgomeryAmy C ShermanJames H MaguireAnn E WoolleyLindsey R BadenNicolas C IssaCourtney E Harris

    Find these authors on Roon

    JL

    Dr. Jessica Little

    Transplant/Immunocompromised States · BWH

    CH

    Dr. Courtney Harris

    Transplant/Immunocompromised States · MUSC

    Summary

    BACKGROUND: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients.METHODS: This multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023. Complications, management, and outcomes were compared between patients with IC/AH (ICAH) and without ICAH (immune intact cohort).RESULTS: Of 225 patients (mean age 66 years, 36% female), 112 were ICAH. ICAH patients had higher median peak parasitemia (2.8% vs 0.9%, P < .0001) and higher rates of complications, including acute kidney injury (24% vs 11%, P = .016) and acute respiratory distress syndrome (11% vs 4%, P = .041), and were more likely to undergo packed red blood cell transfusion (31% vs 17%, P = .023) and exchange transfusion (18% vs 6%, P = .008). Treatment duration was longer in the ICAH cohort (median 27 vs 10 days, P < .001), particularly in those with both IC and AH (median 43 days, P = .003). ICAH patients had higher 12-month all-cause mortality (7% vs 1%, P = .019) and recurrence rates (8% vs 0%, P = .001). Hematologic malignancy (odds ratio = 7.0, P = .023) and B-cell-depleting therapies (odds ratio = 9.4, P = .015) were significant predictors of recurrence. Despite most patients undergoing follow-up testing with blood smears and polymerase chain reaction, these did not reliably predict recurrence.CONCLUSIONS: Patients with ICAH with babesiosis experience more severe disease and higher complication rates. Follow-up testing, including blood smear and polymerase chain reaction, did not reliably predict recurrence, highlighting the need for more effective monitoring strategies in these high-risk populations.
    CHDr. Courtney Harris

    Dr. Courtney Harris

    Infectious Disease · Transplant/Immunocompromised States
    Medical University of South Carolina
    courtneyh